BioCentury | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

...of four applications. China’s National Medical Products Administration extended the label of HDAC inhibitor Epidaza chidamide...
...CD274) - Programmed cell death 1 ligand 1 Paul Bonanos, Associate Editor Imfinzi, durvalumab (MEDI4736) Epidaza, chidamide (CS055, HBI-8000) Keytruda...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

...the case on the main board, he said. The main source of Chipscreen’s revenue, Epidaza chidamide...
...months from the suspension date to report updated financial statements. Hongjiang Li, Staff Writer Epidaza, chidamide (CS055, HBI-8000) Shenzhen...
BioCentury | Jul 31, 2019
Financial News

Chipscreen sets pace for biotech IPOs in Shanghai

...he believes the company’s focus on innovation would attract investors. Chipscreen markets HDAC inhibitor Epidaza chidamide...
BioCentury | Jun 7, 2019
Financial News

Chipscreen set to test Shanghai’s new innovation board

...of RMB19 million ($2.7 million) in 2018, driven by sales of its HDAC inhibitor Epidaza chidamide...
..."Junshi Aims to List on Shanghai's New Innovation Board" ). Hongjiang Li, Staff Writer Epidaza, chidamide (CS055, HBI-8000) BrightGene...
BioCentury | Feb 8, 2016
Company News

Huya, Eisai deal

...Huya granted Eisai exclusive rights to develop and commercialize HBI-8000 for cancer indications in Japan, South...
...Huya has exclusive rights from Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, China) to develop and commercialize HBI-8000...
BioCentury | Feb 2, 2016
Company News

Huya, Eisai strike deal for Chipscreen drug

...Huya Bioscience International LLC (San Diego, Calif.) granted Eisai Co. Ltd. (Tokyo:4523) exclusive rights to HBI-8000...
...from Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, China), which markets the drug in China as Epidaza chidamide...
...candidate in Japan, where it has Orphan Drug designation to treat PTCL, and will manufacture chidamide...
BioCentury | Feb 9, 2015
Clinical News

Epidaza chidamide regulatory update

...China approved Epidaza chidamide from Chipscreen to treat relapsed or refractory peripheral T cell lymphoma (PTCL...
...Research Triangle Park, N.C. Shenzhen Chipscreen Biosciences Ltd. , Shenzhen, China Product: Epidaza chidamide (CS055, HBI-8000...
BioCentury | Oct 21, 2013
Company News

Gold NanoTech, Shenzhen Chipscreen deal

...granted Gold NanoTech's GNT Biotech and Medicals Corp. subsidiary exclusive rights to develop and commercialize Chidamide...
...lymphoma (CTCL) and non-small cell lung cancer (NSCLC). GNT said it will develop and commercialize Chidamide...
BioCentury | Oct 4, 2010
Clinical News

CS055: Phase I started

...Huya began a U.S. Phase I trial to evaluate oral HBI-8000. Huya has exclusive rights from...
...companies are co-developing the compound (see BioCentury, March 12, 2007). Huya and Quintiles are co-developing HBI-8000...
...Research Triangle Park, N.C. Shenzhen Chipscreen Biosciences Ltd. , Shenzhen, China Product: CS055 , HBI-8000...
BioCentury | Jun 15, 2009
Clinical News

Chidamide: Final Phase I data

...advanced solid tumors and lymphomas showed that there were no dose-limiting toxicities in the twice-weekly Chidamide...
...Oncology meeting in Orlando. Patients received 5, 10, 17.5, 25, 32.5 or 50 mg oral Chidamide...
...San Diego, Calif. Shenzhen Chipscreen Biosciences Ltd. , Shenzhen, China Product: Chidamide ( CS055 , HBI-8000...
Items per page:
1 - 10 of 15